Injection, blinatumomab
Products billed under this code include Blincyto.
Payment limit per 1 MCG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Blincyto.
Payment limit per 1 MCG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Blincyto | Amgen Inc | 55513-0160-01 | 35 | $6,056.645 |
| Blincyto | Amgen Inc | 55513-0160-21 | 35 | $6,056.645 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $173.047 | +$0.147 | 1 MCG | Injection, blinatumomab | v1, posted September 17, 2026 |
| 3Q26 | $172.90 | +$8.94 | 1 MCG | Injection, blinatumomab | v1, posted September 15, 2026 |
| 2Q26 | $163.96 | +$0.277 | 1 MCG | Injection, blinatumomab | v1, posted September 15, 2026 |
| 1Q26 | $163.683 | −$0.57 | 1 MCG | Injection, blinatumomab | v1, posted September 15, 2026 |
| 4Q25 | $164.253 | +$1.047 | 1 MCG | Injection, blinatumomab | v1, posted September 8, 2026 |
| 3Q25 | $163.206 | +$10.93 | 1 MCG | Injection, blinatumomab | v1, posted March 10, 2026 |
| 2Q25 | $152.276 | −$0.231 | 1 MCG | Injection, blinatumomab | v1, posted March 10, 2026 |
| 1Q25 | $152.507 | +$0.329 | 1 MCG | Injection, blinatumomab | v1, posted December 19, 2025 |
| 4Q24 | $152.178 | +$0.222 | 1 MCG | Injection, blinatumomab | v1, posted June 11, 2025 |
| 3Q24 | $151.956 | +$6.601 | 1 MCG | Injection, blinatumomab | v1, posted June 11, 2025 |
| 2Q24 | $145.355 | −$0.21 | 1 MCG | Injection, blinatumomab | v1, posted March 11, 2025 |
| 1Q24 | $145.565 | +$0.252 | 1 MCG | Injection, blinatumomab | v1, posted December 19, 2024 |
| 4Q23 | $145.313 | +$0.63 | 1 MCG | Injection, blinatumomab | v1, posted October 10, 2024 |
| 3Q23 | $144.683 | +$8.615 | 1 MCG | Injection, blinatumomab | v1, posted June 5, 2024 |
| 2Q23 | $136.068 | +$0.45 | 1 MCG | Injection, blinatumomab | v1, posted February 23, 2024 |
| 1Q23 | $135.618 | +$3.714 | 1 MCG | Injection, blinatumomab | v1, posted December 6, 2023 |
| 4Q22 | $131.904 | +$2.082 | 1 MCG | Injection, blinatumomab | v1, posted June 22, 2023 |
| 3Q22 | $129.822 | +$5.436 | 1 MCG | Injection, blinatumomab | v1, posted June 9, 2023 |
| 2Q22 | $124.386 | +$0.273 | 1 MCG | Injection, blinatumomab | v1, posted December 14, 2022 |
| 1Q22 | $124.113 | +$0.234 | 1 MCG | Injection, blinatumomab | v1, posted June 8, 2022 |
| 4Q21 | $123.879 | +$1.606 | 1 MCG | Injection, blinatumomab | v1, posted June 2, 2022 |
| 3Q21 | $122.273 | +$4.92 | 1 MCG | Injection, blinatumomab | v1, posted June 2, 2022 |
| 2Q21 | $117.353 | −$0.763 | 1 MCG | Injection, blinatumomab | v1, posted March 1, 2022 |
| 1Q21 | $118.116 | – | 1 MCG | Injection, blinatumomab | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.